Fresenius Kabi SSPC Pharmaceutical Co., Ltd.

Primary objective: To confirm that the effect of SmofKabiven infusion emulsion (study drug) on serum prealbumin levels is non-inferior to the "all-in-one" parenteral nutrition mixture prepared in the hospital (control drug). Secondary objectives: To evaluate the incidence of new postoperative nosocomial infection, prealbumin (day 4), CRP, free fatty acids, TXB3/TXB2, IL-1, IL-2, IL-6, CD4/CD8, taurine levels and safety of SmofKabiven infusion emulsion compared with the "all-in-one" parenteral nutrition mixture prepared in the hospital.

Primary objective: To evaluate and compare the effectiveness of SmofKabiven Peripheral with the "all-in-one" parenteral nutrition mixture prepared in the hospital by observing the effect of the drug on serum prealbumin levels. Secondary objective: To evaluate CRP, free fatty acids, immunological parameters, taurine, safety and preparation time of SmofKabiven Peripheral compared with the "all-in-one" parenteral nutrition mixture prepared in the hospital.

To verify the effectiveness and safety of 1% propofol medium/long chain emulsion injection produced by Huarui Pharmaceutical Co., Ltd. for patients undergoing elective surgery under total intravenous anesthesia